HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thierry P. Carrel Paul R. Vogt Marko I. Turina Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carrel, T. P. Articles by Turina, M. I. Search for Related Content PubMed PubMed Citation Articles by Carrel, T. P. Articles by Turina, M. I.

Ann Thorac Surg 1998;66:153-158
© 1998 The Society of Thoracic Surgeons

---

Original articles: cardiovascular

Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only

^a Clinic for Cardiovascular Surgery, University Hospital, Zürich, Switzerland

Address reprint requests to Dr Carrel, Clinic for Thoracic and Cardiovascular Surgery, University Hospital, CH-3010 Berne, Switzerland
e-mail: (thierry.carrel{at}insel.ch)

Presented at the Poster Session of the Thirty-third Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Feb 3–5, 1997.

Background. The benefits and the current indications of aprotinin in congenital operations are not well defined. At present there are only a few studies available that have investigated a small number of patients in several heterogeneous groups of malformations.

Methods. We investigated efficacy and safety of aprotinin in three groups of children <15 kg, presenting with isolated ventricular septum defect (n = 60), tetralogy of Fallot (n = 52), and transposition of the great arteries (n = 56). Low-dose aprotinin regimen A1 (500,000 KIU in pump prime only) and high-dose aprotinin A2 (50,000 KIU/kg during induction of anesthesia, 50,000 KIU/kg in pump prime, and 20,000 KIU/h continuous infusion) were compared to a control group A0 (without aprotinin) regarding perioperative blood loss, transfusion requirements, and effects on the coagulation system.

Results. The most common coagulation tests of aprotinin-treated patients and the platelet numbers were comparable with those of control patients preoperatively and 15 minutes after protamine administration. A significant dose-dependent reduction in fibrin–fibrinogen split products was observed at the end of cardiopulmonary bypass in the majority of aprotinin-treated patients with transposition. In patients with ventricular septum defect and Fallot, no significant difference in blood loss and transfusion requirements could be observed between patients with or without aprotinin and no difference was observed between low- and high-dose regimen. In transposition of the great arteries, high-dose aprotinin led to significant reduction of blood loss (p = 0.02) and postoperative blood transfusion (p = 0.003). Severe side effects as a result of administration of aprotinin were not observed.

Conclusions. High-dose aprotinin reduces blood loss and transfusion requirement only in complex congenital cardiac operations; therefore aprotinin cannot be recommended as a blood conservation agent in routine pediatric operations.

This article has been cited by other articles:

				C. Murugesan, S. K. Banakal, R. Garg, S. Keshavamurthy, and K. Muralidhar The Efficacy of Aprotinin in Arterial Switch Operations in Infants Anesth. Analg., September 1, 2008; 107(3): 783 - 787. [Abstract] [Full Text] [PDF]

				M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]

				M. M. McCall, M. M. Blackwell, J. T. Smyre, J. J. Sistino, J. R. Acsell, B. H. Dorman, and S. M. Bradley Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial Ann. Thorac. Surg., March 1, 2004; 77(3): 983 - 987. [Abstract] [Full Text] [PDF]

				J. M. Costello, C. L. Backer, A. de Hoyos, H. J. Binns, and C. Mavroudis Aprotinin reduces operative closure time and blood product use after pediatric bypass Ann. Thorac. Surg., April 1, 2003; 75(4): 1261 - 1266. [Abstract] [Full Text] [PDF]

				H. Mossinger, W. Dietrich, S. L. Braun, M. Jochum, H. Meisner, and J. A. Richter High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery Ann. Thorac. Surg., February 1, 2003; 75(2): 430 - 437. [Abstract] [Full Text] [PDF]

				E. R. Stephenson Jr and J. L. Myers Pediatric cardiopulmonary bypass Ann. Thorac. Surg., December 1, 2001; 72(6): 2176 - 2177. [Full Text] [PDF]

				E. A. Bacha, J. Quinones, M. D. Kahana, J. M. Baron, and Z. M. Hijazi Embolic coronary occlusion after the arterial switch procedure J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 1028 - 1030. [Full Text] [PDF]

				H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF]

				L. A. Gramlich and S. D. Barnes Aprotinin Use in Pediatric Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 117 - 121. [Abstract] [PDF]

				M. Codispoti and P. S Mankad Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice Perfusion, May 1, 2000; 15(3): 191 - 201. [Abstract] [PDF]